What does suppressed thyroid‑stimulating hormone, low free thyroxine, normal free triiodothyronine, and normal thyroid peroxidase antibodies indicate, and how should I evaluate and manage it?

Evaluation and Management of Suppressed TSH with Low Free T4, Normal Free T3, and Normal TPO Antibodies

Immediate Diagnostic Interpretation

Your laboratory pattern—TSH 0.27 mIU/L (suppressed), free T4 0.30 ng/dL (low), free T3 2.7 pg/mL (normal), and TPO antibodies 11 IU/mL (normal)—most likely represents central (secondary or tertiary) hypothyroidism, a pituitary or hypothalamic disorder where the TSH response to low thyroid hormone is inappropriately low or absent. 1

This is not subclinical hyperthyroidism, because your free T4 is frankly low, not normal or elevated. 1, 2 This is also not primary hypothyroidism, because TSH would be markedly elevated (not suppressed) in response to low T4. 1

---

Critical Safety Assessment Before Any Treatment

Rule Out Adrenal Insufficiency FIRST

Before initiating levothyroxine therapy, you must exclude concurrent adrenal insufficiency by measuring morning (8 AM) serum cortisol and ACTH, because starting thyroid hormone replacement in the presence of untreated adrenal insufficiency can precipitate life-threatening adrenal crisis. 1, 3

• If morning cortisol is low (<10 mcg/dL) or if clinical features suggest adrenal insufficiency (hypotension, hyponatremia, unexplained fatigue, weight loss, hyperpigmentation), initiate hydrocortisone 20 mg in the morning and 10 mg in the afternoon for at least one week before starting levothyroxine. 1
• In suspected central hypothyroidism or hypophysitis, corticosteroid therapy should always precede thyroid hormone replacement. 1
• Thyroid hormone increases cortisol metabolism; if cortisol reserves are already depleted, levothyroxine can trigger acute adrenal crisis. 1

---

Diagnostic Workup for Central Hypothyroidism

Confirm the Diagnosis

1. Repeat thyroid function tests (TSH, free T4, free T3) after 3–6 weeks to confirm persistent abnormalities, as transient suppression can occur with acute illness, medications, or recovery from nonthyroidal illness. 1, 4

   • 30–60% of mildly abnormal TSH values normalize spontaneously on repeat testing. 1
   • For patients with serious cardiac conditions or symptoms, consider repeating within 2 weeks rather than waiting the full interval. 1

2. Measure additional pituitary hormones to assess for broader pituitary dysfunction (hypopituitarism):

   • Morning cortisol and ACTH (as above)
   • Prolactin (elevated in pituitary stalk compression, low in hypopituitarism)
   • LH, FSH, testosterone (men) or estradiol (women)
   • IGF-1 (growth hormone axis)
   • 1

3. Obtain pituitary MRI with gadolinium contrast to evaluate for:

   • Pituitary adenoma
   • Empty sella syndrome
   • Infiltrative disease (sarcoidosis, hemochromatosis, histiocytosis X)
   • Sheehan syndrome (postpartum pituitary necrosis)
   • Hypophysitis (autoimmune, IgG4-related, or secondary to immune checkpoint inhibitors if applicable)
   • 1

Exclude Non-Thyroidal Causes of TSH Suppression

• Review medications: Dopamine, glucocorticoids, octreotide, metformin, and certain psychiatric medications can suppress TSH. 1, 4
• Assess for recent severe illness or hospitalization: Nonthyroidal illness syndrome (euthyroid sick syndrome) can transiently suppress TSH with low T4 and low or normal T3. 1, 4
• Check for recent iodine exposure (CT contrast, amiodarone): Excess iodine can transiently alter thyroid function. 1

---

Treatment Algorithm for Central Hypothyroidism

Step 1: Initiate Levothyroxine Replacement

Once adrenal insufficiency is excluded or treated, initiate levothyroxine immediately, as untreated central hypothyroidism causes the same metabolic, cardiovascular, and quality-of-life consequences as primary hypothyroidism. 1, 3

Dosing Strategy

• For patients <70 years without cardiac disease or multiple comorbidities: Start levothyroxine at approximately 1.6 mcg/kg/day (typically 100–125 mcg daily for most adults). 1
• For patients >70 years or with cardiac disease/multiple comorbidities: Start at a lower dose of 25–50 mcg/day and titrate gradually by 12.5–25 mcg every 6–8 weeks to avoid unmasking cardiac ischemia or precipitating arrhythmias. 1, 3
• Administer levothyroxine once daily on an empty stomach, 30–60 minutes before breakfast, with a full glass of water. 1, 3
• Separate levothyroxine by at least 4 hours from calcium, iron, antacids, proton pump inhibitors, or other medications that interfere with absorption. 1, 3

Monitoring in Central Hypothyroidism

In central hypothyroidism, TSH cannot be used to monitor adequacy of replacement because the pituitary TSH response is impaired. 1

• Monitor free T4 levels every 6–8 weeks during dose titration, targeting free T4 in the upper half of the normal reference range (or slightly above the midpoint). 1
• Do not rely on TSH, as it will remain low or inappropriately normal even with adequate replacement. 1
• Once stable, recheck free T4 every 6–12 months or if symptoms change. 1
• Assess clinical response: resolution of fatigue, cold intolerance, weight gain, constipation, cognitive slowing, and other hypothyroid symptoms. 1

---

Special Considerations and Common Pitfalls

Cardiovascular Risks

• Untreated hypothyroidism causes cardiac dysfunction (delayed relaxation, reduced cardiac output, increased systemic vascular resistance, diastolic dysfunction), which can manifest as hypertension, heart failure, or bradycardia. 1
• Rapid normalization of thyroid hormone in patients with underlying coronary artery disease can unmask or worsen cardiac ischemia, precipitate myocardial infarction, or trigger arrhythmias. 1, 3
• In elderly patients or those with known cardiac disease, start at 25–50 mcg/day and increase slowly by 12.5–25 mcg every 6–8 weeks. 1
• Obtain baseline ECG to screen for arrhythmias (especially atrial fibrillation) before initiating therapy. 1

Metabolic and Lipid Effects

• TSH >10 mIU/L (in primary hypothyroidism) is associated with elevated LDL cholesterol and triglycerides; central hypothyroidism with low free T4 has similar metabolic consequences. 1
• Treatment with levothyroxine improves lipid profiles and reduces cardiovascular risk. 1

Bone Health

• Overtreatment with levothyroxine (resulting in suppressed TSH and elevated free T4) increases bone resorption and decreases bone mineral density, particularly in postmenopausal women. 1, 3
• In central hypothyroidism, avoid overreplacement by targeting free T4 in the upper-normal range, not supraphysiologic levels. 1
• Ensure adequate calcium (1200 mg/day) and vitamin D (1000 units/day) intake. 1

Pregnancy Considerations

• Women with central hypothyroidism who are pregnant or planning pregnancy require immediate treatment, as untreated maternal hypothyroidism increases risk of preeclampsia, low birth weight, miscarriage, and permanent neurodevelopmental deficits in the child. 1
• Target free T4 in the upper half of the normal range (ideally >1.0 ng/dL or laboratory-specific upper-normal). 1
• Levothyroxine requirements increase by 25–50% during pregnancy; increase the dose immediately upon pregnancy confirmation and monitor free T4 every 4 weeks until stable, then at least once per trimester. 1
• Do not use TSH to guide therapy in central hypothyroidism during pregnancy; rely exclusively on free T4 levels. 1

Autoimmune Screening

• Although your TPO antibodies are normal (11 IU/mL), patients with one autoimmune condition (central hypothyroidism due to hypophysitis) are at increased risk for other autoimmune diseases, including primary adrenal insufficiency (Addison's disease), type 1 diabetes, celiac disease, and pernicious anemia. 1
• Consider screening for 21-hydroxylase antibodies (adrenal autoimmunity), vitamin B12 levels, and tissue transglutaminase antibodies if clinically indicated. 1

---

Critical Pitfalls to Avoid

1. Never start levothyroxine before ruling out adrenal insufficiency in suspected central hypothyroidism—this can precipitate life-threatening adrenal crisis. 1, 3

2. Do not use TSH to monitor therapy in central hypothyroidism—TSH will remain low or inappropriately normal; monitor free T4 instead, targeting the upper half of the normal range. 1

3. Do not assume this is subclinical hyperthyroidism based on low TSH alone—the low free T4 definitively excludes hyperthyroidism and indicates hypothyroidism. 1, 2

4. Do not delay pituitary imaging—central hypothyroidism requires evaluation for structural pituitary or hypothalamic lesions. 1

5. Do not overlook other pituitary hormone deficiencies—isolated central hypothyroidism is rare; most patients have multiple pituitary hormone deficits requiring comprehensive endocrine evaluation. 1

6. Avoid overtreatment—targeting supraphysiologic free T4 levels increases risk of atrial fibrillation (3–5 fold), osteoporosis, fractures, and cardiovascular mortality, especially in patients >60 years. 1, 3

7. Do not treat based on a single set of labs—confirm with repeat testing after 3–6 weeks unless the patient is severely symptomatic or pregnant. 1

---

Summary of Recommended Actions

1. Measure morning cortisol and ACTH immediately to exclude adrenal insufficiency. 1
2. If cortisol is low, start hydrocortisone 20 mg AM / 10 mg PM for at least one week before levothyroxine. 1
3. Repeat TSH, free T4, and free T3 after 3–6 weeks to confirm persistent abnormalities. 1
4. Obtain pituitary MRI with contrast to evaluate for structural lesions. 1
5. Measure additional pituitary hormones (prolactin, LH, FSH, IGF-1, sex hormones) to assess for hypopituitarism. 1
6. Initiate levothyroxine 1.6 mcg/kg/day (or 25–50 mcg/day if elderly or cardiac disease) once adrenal insufficiency is excluded. 1, 3
7. Monitor free T4 (not TSH) every 6–8 weeks during titration, targeting the upper half of the normal range. 1
8. Assess clinical response (resolution of fatigue, cold intolerance, weight gain, cognitive slowing). 1
9. Ensure adequate calcium and vitamin D intake to protect bone health. 1
10. Refer to endocrinology for comprehensive management of central hypothyroidism and potential hypopituitarism. 1